UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 461

Sortiert nach

Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure

Blood advances, 2020-07, Vol.4 (13), p.2866-2870

2020

Link zum Volltext

Verfügbarkeit prüfen

Venetoclax in combination with nucleoside analogs in acute myelogenous leukemia

Current opinion in oncology, 2022-09, Vol.34 (5), p.531

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax

Leukemia research, 2022-11, Vol.122, p.106942-106942, Article 106942

2022

Link zum Volltext

Verfügbarkeit prüfen

Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors

Leukemia & lymphoma, 2023-01, Vol.64 (1), p.188-196

2023

Link zum Volltext

Verfügbarkeit prüfen

Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML)

Leukemia & lymphoma, 2022-11, Vol.63 (13), p.3232-3236

2022

Link zum Volltext

Verfügbarkeit prüfen

FLT3 Inhibitors as Maintenance Therapy after Allogeneic Stem-Cell Transplantation

Blood and lymphatic cancer, 2022-01, Vol.12, p.137-147

2022

Link zum Volltext

Verfügbarkeit prüfen

Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis

Leukemia & lymphoma, 2022-01, Vol.63 (1), p.199-204

2022

Link zum Volltext

Verfügbarkeit prüfen

The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy

American journal of hematology, 2021-05, Vol.96 (5), p.E171-E175

2021

Link zum Volltext

Verfügbarkeit prüfen

RAS Mutations Are Independently Associated with Decreased Overall Survival and Event-Free Survival in Patients with AML Receiving Induction Chemotherapy

Blood, 2019-11, Vol.134 (Supplement_1), p.18-18

2019

Link zum Volltext

Verfügbarkeit prüfen

Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates

Blood advances, 2023-06, Vol.7 (11), p.2360-2363

2023

Link zum Volltext

Verfügbarkeit prüfen

Pulmonary Engraftment Syndrome: A Unique Complication of Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis

Blood, 2022-11, Vol.140 (Supplement 1), p.4726-4727

2022

Link zum Volltext

Verfügbarkeit prüfen

A Phase 1b Study of IDH Inhibition with Enasidenib and MEK Inhibition with Cobimetinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia Who Have Co-Occurring IDH2 and RAS Signaling Gene Mutations

Blood, 2022-11, Vol.140 (Supplement 1), p.11761-11762

2022

Link zum Volltext

Verfügbarkeit prüfen

Trial in Progress: A Phase I Trial of BTX-A51 in Patients with Relapsed or Refractory AML or High-Risk MDS

Blood, 2020-11, Vol.136 (Supplement 1), p.18-19

2020

Link zum Volltext

Verfügbarkeit prüfen

Tocilizumab for the Management of Cytokine Release Syndrome after Haploidentical Hematopoietic Transplant with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis

Blood, 2022-11, Vol.140 (Supplement 1), p.7580-7582

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 461

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(425)
Mit Volltextzugriff
(425)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(461)
Japanisch
(33)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(225)
Life Sciences & Biomedicine
(172)
Humans
(141)
Experiment
(105)
Particle Physics
(103)
Physics
(102)
High Energy Physics - Experiment
(95)
Female
(69)
Male
(66)
Adult
(48)
Physics Of Elementary Particles And Fields
(47)
Biological And Medical Sciences
(42)
Physical Sciences
(41)
Hep
(35)
Animals
(31)
Medical Sciences
(28)
Middle Aged
(28)
Aged
(24)
Adolescent
(23)
Covid-19
(20)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure

Venetoclax in combination with nucleoside analogs in acute myelogenous leukemia

Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax

Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors

Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML)

FLT3 Inhibitors as Maintenance Therapy after Allogeneic Stem-Cell Transplantation

Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis

The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy

RAS Mutations Are Independently Associated with Decreased Overall Survival and Event-Free Survival in Patients with AML Receiving Induction Chemotherapy

Intensive Induction Chemotherapy versus Hypomethylating Agents in Combination with Venetoclax in NPM1-mutant AML

Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates

Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia

Pulmonary Engraftment Syndrome: A Unique Complication of Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis

A Phase 1b Study of IDH Inhibition with Enasidenib and MEK Inhibition with Cobimetinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia Who Have Co-Occurring IDH2 and RAS Signaling Gene Mutations

Trial in Progress: A Phase I Trial of BTX-A51 in Patients with Relapsed or Refractory AML or High-Risk MDS

Initial Results from SELECT-AML-1, a Phase 2 Study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-Positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy

Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Myeloablative Vs Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation in Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

Long Term Outcomes of Patients with Chronic Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation in the Era of Oral Tyrosine Kinase Inhibitors

Tocilizumab for the Management of Cytokine Release Syndrome after Haploidentical Hematopoietic Transplant with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis

Sinusoidal Obstruction Syndrome in Adult Patients with B-Cell Acute Lymphoblastic Leukemia Treated with Inotuzumab Prior to Hematopoietic Stem Cell Transplantation

Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis

Renal Impairment Adversely Impacts Melphalan-Induced Severe GvHD- and GI Toxicity- Free Survival (MGTFS) in Patients Undergoing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation

Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations

Suchergebnisse filtern